Hongwei Ren

Hongwei Ren

Auto-generated profile, based on publicly available information

Hongwei Ren

Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
DIDeena Iskander
Deena Iskander
GWGuanlin Wang
Guanlin Wang
EHElisabeth F. Heuston
Elisabeth F. Heuston
CCChrysi Christodoulidou
Chrysi Christodoulidou
BPBethan Psaila
Bethan Psaila
AKAnastasios Karadimitris
Anastasios Karadimitris
Genotype-phenotype correlations are revealed by bone marrow single-cell RNA sequencing in Diamond-Blackfan anemia.

8 January 2026 in Blood
Verified
Journal Article
Open access
HRHongwei Ren
Hongwei Ren
NENatalina Elliott
Natalina Elliott
BLBryan Lye
Bryan Lye
MSMohammad Umer Sharif Shohan
Mohammad Umer Sharif Shohan
JCJoe W. Cross
Joe W. Cross
AKAnastasios Karadimitris
Anastasios Karadimitris
Current therapies, including autologous chimeric antigen receptor (CAR) T-cell immunotherapy, fail to cure half of infants with KMT2A-rearranged acute lymphoblastic leukemia (KMT2Ar-ALL), a disease characterized by frequent central nervous system involvement, poor treatment response, early relapse, and lineage switching. More effective treatment strategies, including the availability of off-the-shelf immunotherapies, is particularly relevant in infants. PROM1/CD133 is a direct target of KMT2A-fusion oncoproteins and is expressed on leukemic cells. Allogeneic invariant natural killer T (iNKT) cells, “innately” more powerful effectors than T cells, can be deployed off-the-shelf without risk of acute graft-versus-host disease. Here, we equip iNKT cells with CD19- and/or CD133-targeting CARs, and investigate their antileukemia activity against KMT2Ar-ALL in relevant in vitro and in vivo models. Compared with monospecific counterparts and dual, bispecific CAR T cells, bispecific CD19-CD133 CAR-iNKT cells have a more potent antileukemia activity, effectively targeting both CAR antigen–high and –low leukemia. Bispecific CAR-iNKT cells eradicate medullary and, notably, leptomeningeal leukemia, and induce sustained remissions without discernible hematologic toxicity. Mechanistically, the more potent antileukemia effect of CAR-iNKT cells over CAR T cells is mediated by a pronounced CAR-dependent and CAR antigen–dependent upregulation of the innate activating receptor NKG2D on CAR-iNKT cells, and its engagement by its corresponding ligands on KMT2Ar-ALL cells. This ensures effective leukemia targeting even with downregulation of CD133 or CD19. Thus, by engaging with 2 different types of leukemia-associated antigens, that is, CAR antigens and NKG2D ligands, CAR-iNKT cells provide a powerful platform for the treatment of KMT2Ar-ALL. This approach can be readily adapted for other high-risk malignancies, including those with otherwise difficult to target leptomeningeal involvement.